On the morning of March 14, a first-year UCLA medical student named Kayla Gu approached the microphone at a meeting of her university’s Board of Regents. Speaking in a white coat with a stethoscope around her neck, she urged the university to drop a patent claim pending at India’s high court, which the David Geffen
Why Is UCLA Doing Pfizer’s Dirty Work in India?
A university develops a breakthrough prostate cancer drug—and then fights to keep it priced beyond reach.
